I've looked into FYI previously. Here are some comments.
By contrast, ADN's maximum cash requirement is 75% of AUD $28M or $21M. Our Market cap is 3.85 times the cash required to get the project up and running.
- It's very capital intensive. Each $1.00 of CAPEX spend only contributes $2.70 of NPV. i.e. NPV is only 2.7x CAPEX.
- Payback is 3.6 years since the debt burden will be quite high relative to revenue.
- CAPEX is also very high relative to market cap. Currently 12x market cap.
- So with CAPEX at AUD $271M and 30% equity component required that means AUD $81M is required as a condition of finance (30% requirement is written in the DFS). That's 3.6x the current market cap.
- The problem is the company has negotiated a Convertible Note Facility for the equity component. Convertible note facilities generally work out badly for shareholders = massive dilution. Newsflow has to be strong for shareholders to have a chance.
- Project risk is also proportional to CAPEX. The more $$$ spent to get a project running, the more that can go wrong. Many shareholders learnt that from Lithium players.
The after-tax NPV is AUD $511M (100%-basis), which works out to be 18.25 times the $28M required to get the project running. So every $1.00 invested contributes $18.25 to NPV. Compare that with figures for FYI above.
ADN is getting a nimble high-cashflow operation up and running first. I envisage about AUD $40M free cashflow within a couple of years of startup as payback is only 15 months. I expect they will better these numbers with the DFS.
ADN's process plant will effectively be off-the shelf. That's due to the quality of their ore. It's high quality and very pure so they don't need to do much processing to convert it to a top-quality commercial product.
That $40M pa free cashflow that ADN will generate with a first project will go a long way to them getting a HPA operation up and running without burdening/diluting shareholders. They are also planning a different tack. Since their feedstock is so great (4N HPA can be generated in a single processing stage), OPEX will be very competitive. They are also planning to partner reduce the risk (probably with an existing chemical processor).
I will add that ATC have been churning away for about 7 years to get their HPA project running and diluting shareholders 721% in the process. They started with 108M shares on issue and are now 883M shares on issue.
That's all due to the cost / complexity of the project. ATC market cap has moved but the share price hasn't!
- Forums
- ASX - By Stock
- ADN
- Ann: Video Interview with Managing Director
Ann: Video Interview with Managing Director, page-86
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add ADN (ASX) to my watchlist
(20min delay)
|
|||||
Last
0.9¢ |
Change
-0.001(5.56%) |
Mkt cap ! $28.84M |
Open | High | Low | Value | Volume |
0.9¢ | 0.9¢ | 0.9¢ | $18.96K | 2.115M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
39 | 13273901 | 0.8¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
0.9¢ | 14265587 | 19 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
39 | 13273901 | 0.008 |
58 | 32232798 | 0.007 |
41 | 18199490 | 0.006 |
19 | 13877789 | 0.005 |
6 | 7525000 | 0.004 |
Price($) | Vol. | No. |
---|---|---|
0.009 | 14265587 | 19 |
0.010 | 10564677 | 15 |
0.011 | 27376522 | 9 |
0.012 | 30045921 | 7 |
0.013 | 2310111 | 3 |
Last trade - 13.17pm 10/10/2024 (20 minute delay) ? |
Featured News
ADN (ASX) Chart |
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham, MD & CEO
James Graham
MD & CEO
Previous Video
Next Video
SPONSORED BY The Market Online